Author name: ASolia

Axxam is proud to announce that Muna Therapeutics, a biotech company founded in 2020 by Aarhus University, financed by Novo Seeds and receiving assets in exchange of equity from Axxam, was successful closing a EUR 60 million (US$ 73 million) Series A financing round today.

Axxam announces its participation in the REsolution consortium, a public-private research partnership supported by the Innovative Medicines Initiative (IMI), to accelerate research in the field of solute carrier (SLC) class of transporters.

Axxam is proud to announce the entire acquisition of the share capital of Hit Discovery Constance GmbH (“HDC”). As a consequence, HDC founded in 2014 as a joint venture between Axxam, Centre for Drug Design and Discovery of KU Leuven and Lead Discovery Center GmbH, is now a subsidiary of Axxam.

Thanks to the long-standing collaboration with Symeres (recently rebranded from MercachemSyncom), Axxam has access to an additional library of approx. 80,000 lead-like compounds synthetized at Symeres, named Symegold library, for use in high-throughput screens.

Bresso (Italy), Villigen (Switzerland) and Nijmegen (the Netherlands) – Axxam, leadXpro and MercachemSyncom today announced a strategic alliance that will allow them to offer world-class integrated structure-guided drug discovery services for membrane protein targets.

Axxam announces the launch of Libra Therapeutics to develop novel therapies targeting neurodegenerative diseases Sept 24, 2020 Milan (Italy) – Axxam is proud to announce that Libra Therapeutics, a privately held US biotech company founded in mid-2019 by Axxam and focused to develop novel therapies for patients suffering from neurodegenerative diseases as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), raised $29 million in Series A financing round. The financing was co-led by Boehringer Ingelheim Venture Fund, Epidarex Capital, and Santé and the round was joined by Yonjin Venture, Dolby Family Ventures, and Sixty Degree Capital. Libra will use the proceeds of this Series A round to bring proprietary first small molecule products to the clinic and to further expand the pipeline of novel drug candidates targeting neurodegenerative diseases. Axxam has the strategy of taking equity in promising drug discovery companies, by assigning valuable research assets either to already formed companies, such as Acousia Therapeutics GmbH, as well as to start-ups, such as Rewind Therapeutics NV or Libra Therapeutics, Inc. Since 2016, these three drug discovery companies have collected more than EUR 52 million to advance the drug discovery programs transferred from Axxam into later stage development products. For more information please open the Press Release from Libra Therapeutics below or visit www.libratherapeutics.com Open PDF document

Selonterra and Axxam Enter into Drug Discovery Collaboration June 16, 2020 San Mateo, California (USA) and Milan, Italy – Selonterra, Inc., a biotechnology company developing transformative therapies for neurodegenerative disorders, and Axxam S.p.A., a leading discovery research company, announce a collaboration for the identification of novel small molecule therapies for Alzheimer’s disease (AD), based on Selonterra’s proprietary APOE4 mechanism. Through this collaboration, Selonterra will have access to Axxam’s expertise in discovery biology, in particular functional assays, and to its highly diverse and novel small molecule compound collection with the aim of developing small molecules acting on unexploited and highly druggable AD targets identified by Selonterra. Open PDF document

Axxam enters into Drug Discovery Collaboration with Vivozon for CNS Indications May 12, 2020 Axxam announces a collaboration with Vivozon Inc. with the aim to support Vivozon in the development of innovative small molecule drugs for the treatment of patients with unmet CNS medical needs. Thanks to its expertise in early phase discovery biology, Axxam began the collaboration with Vivozon by providing access to a panel of cell-based assays to test Vivozon’s compounds on targets of interest, thereby supporting Vivozon’s scientists in the hit-to-lead program and drug discovery research. Open PDF document